These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18578091)

  • 21. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society.
    Havlir D; Vella S; Hammer S
    AIDS; 2002 Jul; 16(10):7-9. PubMed ID: 12146462
    [No Abstract]   [Full Text] [Related]  

  • 22. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.
    Kouanfack C; Montavon C; Laurent C; Aghokeng A; Kenfack A; Bourgeois A; Koulla-Shiro S; Mpoudi-Ngole E; Peeters M; Delaporte E
    Clin Infect Dis; 2009 May; 48(9):1318-22. PubMed ID: 19320592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal access to HIV/AIDS treatment: challenges ahead.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2009 Dec; 130(6):671-4. PubMed ID: 20090125
    [No Abstract]   [Full Text] [Related]  

  • 24. Outsmarting HIV.
    Fallon SJ
    Posit Aware; 2003; 14(2):37. PubMed ID: 12693374
    [No Abstract]   [Full Text] [Related]  

  • 25. Resisting resistance. A long road of unintentional missteps pays off.
    Sharp M
    Posit Aware; 2007; 18(2):24-5. PubMed ID: 17390486
    [No Abstract]   [Full Text] [Related]  

  • 26. HIV drug resistance testing: data be damned.
    Res Initiat Treat Action; 2000 Dec; 6(4):25-7. PubMed ID: 11708172
    [No Abstract]   [Full Text] [Related]  

  • 27. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L
    Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-resistant human immunodefiency virus.
    Kozal MJ
    Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract]   [Full Text] [Related]  

  • 30. The importance of being earnest. Specific advantages and new treatment options for the un-undetectable.
    Berger DS
    Posit Aware; 2007; 18(2):37. PubMed ID: 17390490
    [No Abstract]   [Full Text] [Related]  

  • 31. HIV drug resistance--a chink in the armor.
    Hirsch MS
    N Engl J Med; 2002 Aug; 347(6):438-9. PubMed ID: 12167687
    [No Abstract]   [Full Text] [Related]  

  • 32. Why HIV drug resistance matters: an overview.
    Learned J
    Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
    [No Abstract]   [Full Text] [Related]  

  • 33. [Tests to detect resistance to antiretroviral agents in clinical practice].
    Seriano Vázquez V; Rodríguez-Rosado y Martínez-Echevarría R; Martínez-Echevarría
    Rev Clin Esp; 1999 Mar; 199(3):179-83. PubMed ID: 10230303
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 35. Outcomes for patients receiving antiretroviral therapy in the developing world appear to be not much different from those in the developed world.
    del Rio C; Priddy F
    Clin Infect Dis; 2005 Jul; 41(2):225-6. PubMed ID: 15983919
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiretroviral drug resistance testing: potential use following nosocomial exposure to HIV.
    Worthington M
    Clin Infect Dis; 2003 Dec; 37(12):1722-3. PubMed ID: 14689361
    [No Abstract]   [Full Text] [Related]  

  • 37. World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries.
    Kuritzkes D; Lange J; Zewdie D
    Nat Med; 2003 Nov; 9(11):1343-4. PubMed ID: 14595419
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiretroviral drug resistance in HIV-infected children: implications for long-term treatment.
    Tudor-Williams G; Green H
    J HIV Ther; 2007 Dec; 12(4):99-100. PubMed ID: 18578093
    [No Abstract]   [Full Text] [Related]  

  • 39. New horizons in antiretroviral drug resistance.
    Geretti AM
    J HIV Ther; 2007 Dec; 12(4):81-2. PubMed ID: 18391891
    [No Abstract]   [Full Text] [Related]  

  • 40. New insights into HIV resistance testing: nursing guidelines and implications.
    Kirton CA; Kurtyka D; Sterken DJ
    J Assoc Nurses AIDS Care; 2007; 18(3):74-86. PubMed ID: 17570302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.